Table 1 Demographic data on IPF patients evaluated in this study
Number of patients (%) | Total | Pirfenidone treatment | No-antifibrotic treatment | P-value (pirfenidone vs no-antifibrotics) |
|---|---|---|---|---|
Patients, % | 601 (100.0%) | 383 (63.7%) | 218 (36.3%) | Â |
Gender (male/female), number (%) | 431 (71.7%)/170 (28.3%) | 281 (73.4%)/102 (26.6%) | 150 (68.8%)/68 (31.2%) | 0.258 |
Age (< 60/60–69/> 70 yrs) | 106/236/259 | 66/157/160 | 40/79/99 | 0.520 |
Smoking status | 0.057 | |||
 Non smokers | 275 (45.8%) | 166 (43.3%) | 109 (50.0%) |  |
 Exsmokers | 316 (52.6%) | 213 (55.6%) | 103 (47.2%) |  |
 Smokers | 10 (1.7%) | 4 (1.0%) | 6 (2.8%) |  |
FVC (%), predicted, at the treatment initiation Mean ± SD | 71.7 ± 15.9 | 70.7 ± 13.2 | 74.2 ± 20.8 | 0.068 |
DLCO (%), predicted, at the treatment initiation Mean ± SD | 46.1 ± 13.6 | 47.8 ± 12.1 | 41.9 ± 16.1 | < 0.001 |
FVC ≥50% and ≤ 90% predicted & DLCO ≥ 35%, yes/no, number (%) | 432/169 (71.9%/28.1%) | 322/61 (84.1%/15.9%) | 110/108 (50.5%/49.5%) | < 0.001 |